SEMA4D expression has been associated with bone metastasis in breast and distant metastasis across various other cancers, which led to the development of the monoclonal antibody pipinemab, currently undergoing clinical evaluation in breast, pancreatic and head and neck cancers. This evidence concerns the gene SEMA4D and cancer.